What are the benefits of antiplatelet and anticoagulant therapy for patients with prior CABG and NSTE-ACS?
Patients with prior CABG and NSTE-ACS should receive antiplatelet and anticoagulant therapy according to GDMT as these patients are at an increased risk of developing disease progression of ungrafted native vessels or significant atherothrombotic disease in saphenous vein grafts and subsequent ACS. In the PURSUIT trial, 12% of the patients had prior CABG and more adverse follow-up outcomes, including increased mortality, but had a benefit with eptifibatide similar to those without prior CABG. Early catheterization after NSTEMI is also less likely for these patients.